NCT05306288

Brief Summary

CASCADE-LUNG is a multisite, prospective, observational, blood specimen collection study in the elevated-risk lung cancer screening population. The primary objective is to demonstrate the performance characteristics, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the DELFI Lung Cancer Screening Test (DLCST) for the detection of pathologically-confirmed lung cancer in a screening population using LDCT, pathology, and follow-up as the reference method.

Trial Health

78
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11,935

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started Apr 2022

Longer than P75 for all trials

Geographic Reach
2 countries

67 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Apr 2022Oct 2026

First Submitted

Initial submission to the registry

March 23, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 1, 2022

Completed
6 days until next milestone

Study Start

First participant enrolled

April 7, 2022

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2026

Last Updated

March 19, 2026

Status Verified

March 1, 2026

Enrollment Period

4.2 years

First QC Date

March 23, 2022

Last Update Submit

March 17, 2026

Conditions

Keywords

Lung Cancer Screening

Outcome Measures

Primary Outcomes (1)

  • Performance characteristics (sensitivity, specificity, PPV, NPV) of the DLCST.

    Approximately 24 months

Secondary Outcomes (2)

  • Performance characteristics (sensitivity, specificity, PPV, NPV) of the DLCST.

    Up to approximately 36 months

  • Adverse events (AEs) associated with the blood specimen collection.

    Point in time blood collection (1 day) at enrollment

Study Arms (1)

Individuals with elevated-risk lung cancer (screening population)

Other: Blood Sample Collection

Interventions

Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days after enrollment.

Individuals with elevated-risk lung cancer (screening population)

Eligibility Criteria

Age50 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants will be men and women, current or former smokers, ≥ 50 years of age who are scheduled for a standard-of-care screening chest CT scan.

You may qualify if:

  • All subjects
  • Ability to understand and provide written informed consent
  • Age ≥ 50 years
  • Current or former smoker
  • ≥ 20 pack-years (pack years = number of packs per day Ă— number of years smoked)
  • An initial or annual follow-up lung cancer screening chest CT planned/scheduled within 30 days after enrollment (i.e., enrollment chest CT scan)

You may not qualify if:

  • All subjects
  • Evidence of any diagnosed cancer (including prior lung cancer) other than non-melanoma skin cancer or carcinoma in situ within 2 years prior to enrollment
  • Prior systemic therapy, definitive therapy, radiation, or surgical resection for any cancer diagnosis within 2 years prior to enrollment (with the exception of surgery for nonmelanoma skin cancer and biopsies)
  • Any history of hematologic malignancy or myelodysplasia within 2 years prior to enrollment
  • Any history of organ tissue transplantation
  • Any history of blood product transfusion within 120 days prior to enrollment
  • Current pregnancy
  • Any condition that in the opinion of the Investigator should preclude the participant's participation in the study
  • Past or current participation in any clinical study sponsored by DELFI Diagnostics or any history of a LDT (Laboratory Developed Test) for early detection of lung cancer by DELFI Diagnostics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (67)

Cullman Clinical Trials

Cullman, Alabama, 35055, United States

Location

Science 37 (nationwide digital enrollment)

Culver City, California, 90230, United States

Location

Providence Facey Medical Foundation

Mission Hills, California, 91345, United States

Location

Hoag Hospital

Newport Beach, California, 92663, United States

Location

Paradigm Clinical Research Center, Inc.

Redding, California, 96001, United States

Location

San Francisco VA

San Francisco, California, 94121, United States

Location

Clinical Research of California LLC

Walnut Creek, California, 94598, United States

Location

SCL Health Research Institute, St. Mary's

Grand Junction, Colorado, 81501, United States

Location

Paradigm Clinical Research Center

Wheat Ridge, Colorado, 80033, United States

Location

Stamford Health

Stamford, Connecticut, 06904, United States

Location

Advanced Research

Boynton Beach, Florida, 33347, United States

Location

Morton Plant Hospital

Clearwater, Florida, 33756, United States

Location

SIMEDHealth, LLC

Gainesville, Florida, 32607, United States

Location

Galenus Group

Lehigh Acres, Florida, 33936, United States

Location

Renstar Medical Research

Ocala, Florida, 34470, United States

Location

United Medical Research

Port Orange, Florida, 32127, United States

Location

American Clinical Trials, LLC.

Acworth, Georgia, 30101, United States

Location

Centricity Research Columbus Piedmont

Columbus, Georgia, 31904, United States

Location

ClinCept, LLC

Columbus, Georgia, 31904, United States

Location

Coastal Heritage Clinical Research

Hinesville, Georgia, 31313, United States

Location

Centricity Research Gwinnett Pulmonology

Lawrenceville, Georgia, 30046, United States

Location

Centricity Research Rincon Pulmonology

Rincon, Georgia, 31326, United States

Location

OSF Saint Francis Medical Center

Peoria, Illinois, 61637, United States

Location

Springfield Clinic

Springfield, Illinois, 62703, United States

Location

St. Elizabeth Healthcare

Edgewood, Kentucky, 41017, United States

Location

Ochsner

New Orleans, Louisiana, 70121, United States

Location

Johns Hopkins

Baltimore, Maryland, 21224, United States

Location

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

Location

Henry Ford Hospital

Detroit, Michigan, 48202, United States

Location

Pulmonary Research Institute of Southeast Michigan

Farmington Hills, Michigan, 48336, United States

Location

Minneapolis VA

Minneapolis, Minnesota, 55417, United States

Location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Hannibal Regional Healthcare System

Hannibal, Missouri, 63401, United States

Location

Washington University

St Louis, Missouri, 63110, United States

Location

Missouri Baptist Medical Center

St Louis, Missouri, 63131, United States

Location

Somnos Clinical Research

Lincoln, Nebraska, 68510, United States

Location

Internal Medicine Associate

Bridgeton, New Jersey, 08302, United States

Location

CHRISTUS St. Vincent Regional Medical Center

Santa Fe, New Mexico, 87505, United States

Location

University of Rochester Medical Center

Rochester, New York, 14642, United States

Location

SUNY Upstate Medical University

Syracuse, New York, 13210, United States

Location

University of North Carolina Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Location

Duke University

Durham, North Carolina, 27705, United States

Location

Durham VA

Durham, North Carolina, 27705, United States

Location

Coastal Carolina Health Care, P.A.

New Bern, North Carolina, 28562, United States

Location

University of Cincinnati Medical Center

Cincinnati, Ohio, 45069, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Hightower Clinical

Oklahoma City, Oklahoma, 73134, United States

Location

Northwest Research Center

Portland, Oregon, 97202, United States

Location

Oregon Health Sciences University

Portland, Oregon, 97239, United States

Location

Clinical Research Associates of Central Pa, LLC

DuBois, Pennsylvania, 15801, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

Location

Pittsburgh VA Healthcare System

Pittsburgh, Pennsylvania, 15217, United States

Location

Allegheny Health Network

Pittsburgh, Pennsylvania, 15224, United States

Location

Ralph H Johnson VA

Charleston, South Carolina, 28401, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29407, United States

Location

LLM Research

Myrtle Beach, South Carolina, 29577, United States

Location

Baptist Clinical Research Institute

Memphis, Tennessee, 38120, United States

Location

Greater Heights Memorial Pulmonary and Sleep

Houston, Texas, 77008, United States

Location

Houston Pulmonary Sleep and Allergy Associates

Houston, Texas, 77070, United States

Location

North Houston Cancer Clinics

Huntsville, Texas, 77340, United States

Location

CHRISTUS Trinity Clinic Pulmonary Medicine

Irving, Texas, 75038, United States

Location

R&H Clinical Research, Inc.

Katy, Texas, 77494, United States

Location

Lumi Research

Kingwood, Texas, 77339, United States

Location

Central Virginia VA Health System: Hunter Holmes McGuire

Richmond, Virginia, 23249, United States

Location

UW Medicine Valley Medical Center

Renton, Washington, 98055, United States

Location

Pan American Center for Oncology Trials

San Juan, 902, Puerto Rico

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood specimens will be de-identified and may be used to develop and evaluate performance of biomarker assays to detect cancers or other conditions, laboratory process improvements, and proficiency testing.

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 23, 2022

First Posted

April 1, 2022

Study Start

April 7, 2022

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

October 30, 2026

Last Updated

March 19, 2026

Record last verified: 2026-03

Locations